Supply chain leveraging is being financed co-led by new investors Sofinnova Investments and B Capital, along with an existing investor with continued support from F-Prime, Omega Funds, and Third Rock Ventures. Additional new investors include Qatar Investment Authority and Alexandria Venture Investments.
Funding will support the advancement of lead asset AB001 through phase II development, the progress of additional undisclosed programs toward IND readiness, and the expansion of a unique supply chain leveraging Artbio’s proprietary generator technology.
Artbio, a clinical-stage radiopharmaceutical company developing a new class of alpha radioligand therapies (ARTs) to treat a range of cancers, has announced the closing of a $132m series B financing. These proceeds will be used to advance the company’s development of ARTs.
This latest round of funding will support the advancement of Artbio’s pipeline, including its lead program, AB001, for metastatic castration-resistant prostate cancer, through phase II clinical trials, and enable continued expansion of the company’s supply chain. The company plans to rapidly advance its manufacturing network infrastructure to supply global clinical trials, and ultimately, commercialization.
A critical enabler of Artbio’s success is its patented AlphaDirect™ isotope isolation technology, which enables flexible production of clinical-grade lead-212 (212Pb) and therapeutic doses daily. This is achieved by a strategically distributed manufacturing network, improving access and de-risking common supply chain issues.
About Artbio
Artbio is a clinical-stage radiopharmaceutical company redefining cancer care by creating a new class of alpha radioligand therapies (ARTs). Artbio is advancing multiple pipeline programs with lead program AB001 in metastatic castration resistant prostate cancer currently in first in human trials.
